EUROSPK Study Group

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

1 in Phase 3

Quick facts

Phase 3 pipeline

sirolimus versus mycophenolate mofetil · Immunology / Transplantation
This is a comparative study of two immunosuppressive agents: sirolimus (mTOR inhibitor) and mycophenolate mofetil (IMPDH inhibitor), used to prevent organ rejection.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

EUROSPK Study Group portfolio CI brief
EUROSPK Study Group pipeline updates RSS

Frequently asked questions about EUROSPK Study Group

What is EUROSPK Study Group's pipeline?

EUROSPK Study Group has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include sirolimus versus mycophenolate mofetil.

Sector hub: All tracked pharma companies